Home

Welcome to Quest PharmaTech Inc.

Quest PharmaTech is a publicly traded (QPT:TSXV), Canadian based pharmaceutical company developing products to improve the quality of life through investee companies and proprietary technologies. Quest is developing an antibody licensed from the University of Nebraska, Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications.

Notes:

1. OncoQuest transferred its immunotherapy assets to OncoQuest Pharmaceuticals, Inc. (“OQP”) in return for convertible bonds and a corporate bond of OQP. The OQP bonds will be exchanged into bonds of Canaria Bio M and are planned to be exchangeable ultimately into shares of Canaria Bio. OncoQuest issued an in-kind dividend of OQP bonds to its shareholders on January 14, 2022. Quest’s portion, fully diluted, is approximately KRW 129.1 billion face value of OQP bonds.

2. Quest has an 10.67 % direct ownership interest in OncoVent. Quest also has a 12% indirect interest through its ownership interest in OncoQuest. OncoQuest owns 29% of OncoVent.

Press releases 2024

January 30, 2024
Quest Receives Cash Dividend Payment from OncoQuest

January 23, 2024
Oregovomab Phase III Clinical Study fails futility analysis; Data Safety Monitoring Board Recommends Overall Survival Follow Up for Potential Late Immune Effects and Clinical Benefits

Press releases 2023

September 13, 2023
Quest PharmaTech Provides Corporate Update

July 14, 2023
Quest PharmaTech Announces Results from AGM

July 10, 2023
Quest PharmaTech Provides Product Development Update

June 6, 2023
Quest PharmaTech Clarifies Agreement in Principle with OQP Bio Inc.

June 2, 2023
Quest PharmaTech Provides Corporate Update

Press releases 2022

September 28, 2022
Quest PharmaTech Announces Sale of Bioceltran Investment and Return of Photodynamic Therapy Technology License

April 19, 2022
Quest PharmaTech Provides Corporate Update

Press releases 2021

September 1, 2021
OncoQuest Pharmaceuticals Inc. Announces First Patient Enrolled in Each of Two Investigator Initiated Clinical Trials of Oregovomab in Combination Therapy for the Treatment of Recurrent Ovarian Cancer

July 7, 2021
Quest PharmaTech Announces Results from AGM

June 1, 2021
Quest PharmaTech Announces two presentations by OncoQuest Pharmaceuticals, Inc. at the 2021 Annual Meeting of the American Association of Clinical Oncologists

March 26, 2021
Quest Provides Update to Immunotherapy Asset Transfer Between OncoQuest Inc. and OncoQuest Pharmaceuticals Inc.

February 2, 2021
Quest Provides Update to Immunotherapy Asset Transfer Between OncoQuest Inc. and OncoQuest Pharmaceuticals Inc.

January 5, 2021
Quest Provides Update to Immunotherapy Asset Transfer Between OncoQuest Inc. and OncoQuest Pharmaceuticals Inc.

Press releases 2020

November 9, 2020
Quest Announces that OncoQuest Pharmaceuticals Inc. Doses First Patient in Phase 3 Clinical Trial, FLORA-5, of Company’s Lead Investigational Drug, Oregovomab, in Frontline Ovarian Cancer and appoints Dr. Sunil Gupta as Chief Medical Officer

June 4, 2020
Quest Provides Corporate Update

May 29, 2020
Quest Provides Additional Information on OncoQuest Transaction and Announces Delay in Annual Filings

April 22, 2020
OncoQuest Signs a Definitive Agreement to Sell Drug Portfolio to Dual Industrial for U.S. $300 Million and Commitment to Fund the Oregovomab Phase 3 Clinical Trial in Frontline Ovarian Cancer

March 24, 2020
OncoQuest Announces Publication of Two Reports Related to Oregovomab Phase 2 Clinical Trial, the Company’s Lead Investigational Drug in Frontline Ovarian Cancer

March 13, 2020
OncoQuest Announces a U.S.$50 Million Investment by KOSDAQ listed Dual Industrial Co. Ltd.